27 related articles for article (PubMed ID: 10664251)
1. Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
Van Laar R; Lincoln M; Van Laar B
Br J Cancer; 2018 Mar; 118(6):857-866. PubMed ID: 29360813
[TBL] [Abstract][Full Text] [Related]
2. Blood Biomarkers of Uveal Melanoma: Current Perspectives.
Bande Rodríguez MF; Fernandez Marta B; Lago Baameiro N; Santiago-Varela M; Silva-Rodríguez P; Blanco-Teijeiro MJ; Pardo Perez M; Piñeiro Ces A
Clin Ophthalmol; 2020; 14():157-169. PubMed ID: 32021081
[TBL] [Abstract][Full Text] [Related]
3. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.
Heneghan HM; Miller N; Kelly R; Newell J; Kerin MJ
Oncologist; 2010; 15(7):673-82. PubMed ID: 20576643
[TBL] [Abstract][Full Text] [Related]
4. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
6. Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.
Mohammed MQ; Abraha HD; Sherwood RA; MacRae K; Retsas S
Med Oncol; 2001; 18(2):109-20. PubMed ID: 11778756
[TBL] [Abstract][Full Text] [Related]
7. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
8. [S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].
Ortiz B; Vázquez C; Martínez C; Giménez J; Sanmartín O; de los Dolores V; Ortega F; Maíquez J; Fliquete MV
Rev Esp Med Nucl; 2003; 22(2):87-96. PubMed ID: 12646097
[TBL] [Abstract][Full Text] [Related]
9. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay.
Wollina U; Karte K; Hipler UC; Knöll B; Kirsch K; Herold C
J Cancer Res Clin Oncol; 2000 Feb; 126(2):107-10. PubMed ID: 10664251
[TBL] [Abstract][Full Text] [Related]
10. [S-100 beta protein in serum, a tumor marker in malignant melanoma-- current state of knowledge and clinical experience].
Jäckel A; Deichmann M; Waldmann V; Bock M; Näher H
Hautarzt; 1999 Apr; 50(4):250-6. PubMed ID: 10354916
[TBL] [Abstract][Full Text] [Related]
11. Serological markers for melanoma.
Brochez L; Naeyaert JM
Br J Dermatol; 2000 Aug; 143(2):256-68. PubMed ID: 10951131
[TBL] [Abstract][Full Text] [Related]
12. Quantification of melanoma-associated molecules in plasma/serum of melanoma patients.
Hauschild A; Gläser R; Christophers E
Recent Results Cancer Res; 2001; 158():169-77. PubMed ID: 11092044
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
